Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Summary
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Official title: Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma in the Post-Marketing Setting
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2025-02-04
Completion Date
2044-09-30
Last Updated
2025-02-24
Healthy Volunteers
No
Conditions
Interventions
Lisocabtagene maraleucel
According to US Prescribing Information
Locations (1)
Center for International Blood and Marrow Transplant Research (CIBMTR)
Milwaukee, Wisconsin, United States